Stock News

Schwartz Investment Counsel Has Lowered Its Ametek New (AME) Position; Next Century Growth Investors Has Trimmed By $971,834 Its Regeneron Pharmaceuticals (REGN) Stake

Schwartz Investment Counsel Inc decreased Ametek Inc New (AME) stake by 27.02% reported in 2017Q3 SEC filing. Schwartz Investment Counsel Inc sold 98,100 shares as Ametek Inc New (AME)’s stock rose 10.20%. The Schwartz Investment Counsel Inc holds 265,000 shares with $17.50M value, down from 363,100 last quarter. Ametek Inc New now has $17.65B valuation. The stock increased 0.83% or $0.63 during the last trading session, reaching $76.35. About 1.26 million shares traded or 4.93% up from the average. AMETEK, Inc. (NYSE:AME) has risen 27.71% since February 22, 2017 and is uptrending. It has outperformed by 11.01% the S&P500.

Next Century Growth Investors Llc decreased Regeneron Pharmaceuticals (REGN) stake by 56.22% reported in 2017Q3 SEC filing. Next Century Growth Investors Llc sold 2,179 shares as Regeneron Pharmaceuticals (REGN)’s stock rose 21.24%. The Next Century Growth Investors Llc holds 1,697 shares with $758,000 value, down from 3,876 last quarter. Regeneron Pharmaceuticals now has $34.16B valuation. The stock decreased 1.71% or $5.53 during the last trading session, reaching $317.51. About 946,763 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has risen 17.40% since February 22, 2017 and is uptrending. It has outperformed by 0.70% the S&P500.

Next Century Growth Investors Llc increased Square Inc stake by 30,667 shares to 124,287 valued at $3.58M in 2017Q3. It also upped Eagle Materials Inc (NYSE:EXP) stake by 8,619 shares and now owns 111,208 shares. Norwegian Cruise Line Holdings (NASDAQ:NCLH) was raised too.

Investors sentiment decreased to 1.17 in Q3 2017. Its down 0.21, from 1.38 in 2017Q2. It dropped, as 56 investors sold REGN shares while 165 reduced holdings. 71 funds opened positions while 187 raised stakes. 73.70 million shares or 3.04% more from 71.53 million shares in 2017Q2 were reported. Ibm Retirement Fund holds 0.18% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) or 1,968 shares. Fiera Corporation holds 0.01% or 4,278 shares. Ny State Common Retirement Fund accumulated 226,909 shares. Morgan Stanley has invested 0.06% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Natixis Asset Mgmt owns 0.06% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 1,524 shares. Oakbrook Invs Ltd Company has 0.1% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Iberiabank invested in 0.36% or 4,793 shares. Bnp Paribas Arbitrage Sa invested in 475,804 shares or 0.52% of the stock. Alpine Glob Management Ltd Liability Com invested in 0.09% or 734 shares. Rhenman And Ptnrs Asset Mngmt Ab owns 22,000 shares for 1.26% of their portfolio. Diversified Tru holds 0.12% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 3,605 shares. Mason Street Advsr Limited Liability invested in 0.12% or 10,665 shares. Bb Biotech Ag invested in 2.54% or 205,000 shares. Lazard Asset Mgmt Limited Liability, a New York-based fund reported 4 shares. The New York-based Joel Isaacson & Co Ltd Com has invested 0.25% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Among 33 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 13 have Buy rating, 1 Sell and 19 Hold. Therefore 39% are positive. Regeneron Pharmaceuticals Inc. had 118 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) earned “Neutral” rating by Chardan Capital Markets on Monday, August 31. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has “Buy” rating given on Thursday, February 25 by Citigroup. Jefferies maintained the shares of REGN in report on Friday, February 2 with “Hold” rating. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) earned “Buy” rating by Leerink Swann on Tuesday, August 15. The stock has “Hold” rating by Citigroup on Tuesday, January 9. On Monday, September 11 the stock rating was maintained by BMO Capital Markets with “Hold”. Morgan Stanley maintained the stock with “Equal-Weight” rating in Thursday, November 9 report. The rating was maintained by Leerink Swann with “Outperform” on Monday, April 4. Robert W. Baird downgraded Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Friday, August 5 to “Neutral” rating. The rating was initiated by Wells Fargo on Friday, December 4 with “Outperform”.

Analysts await Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to report earnings on May, 3. They expect $5.08 earnings per share, up 135.19% or $2.92 from last year’s $2.16 per share. REGN’s profit will be $546.57 million for 15.63 P/E if the $5.08 EPS becomes a reality. After $4.46 actual earnings per share reported by Regeneron Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 13.90% EPS growth.

Since August 23, 2017, it had 0 insider purchases, and 5 insider sales for $2.48 million activity. Another trade for 72,378 shares valued at $34.84M was made by Sanofi on Friday, August 25. GOLDSTEIN JOSEPH L also sold $325,600 worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Friday, February 9. Landry Robert E had sold 427 shares worth $210,693 on Wednesday, August 30. Shares for $900,000 were sold by BAKER CHARLES A. BROWN MICHAEL S sold $712,500 worth of stock.

Since September 19, 2017, it had 0 buys, and 8 insider sales for $15.98 million activity. $227,550 worth of AMETEK, Inc. (NYSE:AME) shares were sold by VARET ELIZEBETH R. $10.01M worth of stock was sold by HERMANCE FRANK S on Wednesday, September 20. 14,976 shares were sold by Oscher Ronald J, worth $1.13 million on Thursday, February 15. $1.86 million worth of AMETEK, Inc. (NYSE:AME) was sold by ZAPICO DAVID A. $817,215 worth of AMETEK, Inc. (NYSE:AME) was sold by Marecic Thomas C on Tuesday, September 19. EGINTON WILLIAM D sold 16,368 shares worth $1.26M.

Schwartz Investment Counsel Inc increased Priceline Grp Inc (NASDAQ:PCLN) stake by 2,800 shares to 6,300 valued at $11.53M in 2017Q3. It also upped Axalta Coating Sys Ltd stake by 36,000 shares and now owns 273,300 shares. Liberty Interactive Corp (NASDAQ:QVCA) was raised too.

Analysts await AMETEK, Inc. (NYSE:AME) to report earnings on May, 1. They expect $0.72 earnings per share, up 20.00% or $0.12 from last year’s $0.6 per share. AME’s profit will be $166.41 million for 26.51 P/E if the $0.72 EPS becomes a reality. After $0.70 actual earnings per share reported by AMETEK, Inc. for the previous quarter, Wall Street now forecasts 2.86% EPS growth.

Leave a Reply

Your email address will not be published. Required fields are marked *